Naloxegol for the treatment of opioid-induced constipation

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 8, 2014, Pages 855-861

  Tack, Jan ^a   Corsetti, Maura ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Naloxegol; Opioid withdrawal; Opioid induced constipation; Randomized controlled clinical trial

Indexed keywords

DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MORPHINE; NALOXEGOL; NALOXONE; OPIATE; PLACEBO; MACROGOL DERIVATIVE; MORPHINAN DERIVATIVE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC PAIN; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; FLATULENCE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRANSIT; HEADACHE; HUMAN; NAUSEA; NONHUMAN; OPIOID INDUCED CONSTIPATION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VOMITING; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL;

ANALGESICS, OPIOID; ANIMALS; CONSTIPATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MORPHINANS; NARCOTIC ANTAGONISTS; POLYETHYLENE GLYCOLS;

EID: 84911387800     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.939629     Document Type: Article

References (32)

1. Manchikanti L, Helm S 2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician 2012:15(3 Suppl):ES9-38
2. Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012;72(14):1847-65
3. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009;155(1-3):11-17
4. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004;112(3):372-80
5. Sykes NP. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 1998;12(5):375-82
6. Lapane KL, Quilliam BJ, Benson C, et al. Gastrointestinal events after opioid treatment in nonmalignant pain: correlates of occurrence and impact on health-related quality of life. J Opioid Manag 2013;9(3):205-16
7. Bell T, Annunziata K, Leslie JB. Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: findings from the National Health and Wellness Survey. J Opioid Manag 2009;5(3):137-44
8. Tack J, Müller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol 2009;7(5):502-8
9. Caraceni A, Hanks G, Kaasa S, European Palliative Care Research Collaborative (EPCRC); European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012;13(2):e58-68
10. Candy B, Jones L, Goodman ML, et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011(1):CD003448
11. Twycross RG, McNamara P, Schuijt C, et al. Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study. Palliat Med 2006;20(4):419-23
12. Cryer BL, Katz S, Vallejo R, et al. A phase 3, randomized, double-blind, placebo-controlled clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction in patients with chronic, non-cancer pain. Gastroenterology 2010;138(suppl 1):S129
13. Sloots CE, Rykx A, Cools M, et al. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 2010;55(10):2912-21
14. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 2002;23:48-53
15. Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010;10:12
16. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13(1):56-64
17. Burness CB, Keating GM. Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs 2014;74(3):353-75
18. Mercadante S, Ferrera P, Adile C. High doses of oxycodone-naloxone combination may provide poor analgesia. Support Care Cancer 2011;19(9):1471-2
19. Mackey AC, Green L, Greene P, Avigan M. Methylnaltrexone and gastrointestinal perforation. J Pain Symptom Manage 2010;40(1):e1-3
20. Ford AC, Brenner DM, Schoenfeld PS. Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis. Am J Gastroenterol 2013;108(10):1566-74
21. Vaughan-Shaw PG, Fecher IC, Harris S, Knight JS. A meta-analysis of the effectiveness of the opioid receptor antagonist alvimopan in reducing hospital length of stay and time to GI recovery in patients enrolled in a standardized accelerated recovery program after abdominal surgery. Dis Colon Rectum 2012;55(5):611-20
22. GlaxoSmithKline and Adolor Corporation. GSK and Adolor announce preliminary results from phase 3 safety study of alvimopan (Entereg/Entrareg). Available from: www.gsk.com/media/press-releases/2007/gsk-and-adolor-announce-preliminary-results-from-phase-3-safety-study-of-alvimopan-enteregentrareg.html [Last accessed 30 March 2014]
23. Oral NKTR-118 (oral PEG-naloxol), a PEGylated derivative of naloxone; demonstration of selective peripheral opioid antagonism after oral administration in preclinical models. Poster presented at the American Academy of Pain Management Meeting in Las Vegas, Nevada - 28 September 2007. Available from: www.nektar.com/pdf/pipeline/NKTR-118/NKTR-118-aapm-2007-preclinical-data-poster-28.pdf [Last accessed on 30 March 2014]
24. NKTR-118, An oral peripheral opioid antagonist, has low potential for drug-drug interactions. Poster presented at the ACCP 38th Annual Meeting - 13 September 2008. Available from: www.nektar.com/pdf/pipeline/NKTR-118/ACCP38thAnnual MeetingPoster141.pdf [Last accessed on 30 March 2014]
25. Evaluation of PEG-naloxol NKTR-118 as an oral peripheral opioid antagonist in healthy male subjects: a double-blind, placebo-controlled, dose escalation crossover study. Poster presented at the American College of Clinical Pharmacology 36th Annual Meeting in San Francisco, CA - 10 September 2007. Available form: www.nektar.com/pdf/pipeline/NKTR-118/NKTR-118-aacp2007-single-dose-phase-1-trial.pdf [Last accessed on 30 March 2014]
26. "Comparative bioavailability of NKTR-118 tablets and solution: a case of bioequivalence between dosage forms for a rapidly absorbed drug". Poster presented at the ACCP 38th Annual Meeting - 13 September 2008. Available form: www.nektar.com/pdf/pipeline/NKTR-118/ACCP38thAnnualMeetingPoster140.pdf [Last accessed on 30 March 2014]
27. Gottfridsson C, Carlson G, Lappalainen J, Sostek M. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers. Clin Ther 2013;35(12):1876-83
28. Webster L, Dhar S, Eldon M, et al. A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain 2013;154:1542-50
29. Chey WD, Webster L, Sostek M, Tack J. Efficacy and safety of naloxegol in patients with opioid-induced constipation: results from 2 prospective, randomized, controlled trials. Gastroenterology 2013;144(5Supp 1): S159-60; abstract
30. Tack J, Chey WD, Webster L, et al. Efficacy of naloxegol in a subpopulation of patients with opioid-induced constipation and an inadequate baseline response to laxatives: results from 2 prospective, randomized, controlled trials. United European Gastroenterol J 2013;1(suppl 1): A49; abstract
31. AstraZeneca announces top-line phase III results from naloxegol pivotal trials in patients with opioid-induced constipation. Available from: www.astrazeneca.com/Media/Press-releases/Article/20121211-astrazeneca-announces-topline [Last accessed 30 March 2014]
32. Von Roenn JH, Tack J, Barker PN, et al. Challenges in patient recruitment during KODIAC-06, a randomized, placebo-controlled, double-blind, multicenter, phase 3 trial of naloxegol in patients with neoplasia and opioid-induced constipation. Presented at the International Symposium on Supportive Care in Cancer, Berlin; 27-29 June 2013. Available from: http://mascc.meetingxpert.net/MASCC-466/poster-67568/program.aspx. [Last accessed on 30 March 2014]